Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02588053 · ClinicalTrials.gov registry record
Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?
A clinical trial of Multiple Sclerosis, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 85
- Enrollment target
- 1
- Study location
NCT02588053 is a study of Multiple Sclerosis that has completed, run by University of Colorado, Denver. The registered enrollment target is 85 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02588053, a study of Multiple Sclerosis, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 85 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary Aims: To determine how effective long term Natalizumab (NTZ) therapy is in slowing the progression of whole brain atrophy. Whole brain atrophy rates will be measured through magnetic resonance imaging (MRI) scans and compared between patients with Multiple Sclerosis (MS) who have been using NTZ for at least 2 years versus age and gender-matched healthy controls. The primary outcome will be whole brain atrophy rate measured as the percent change in brain volume (PBVC) over a two-year period. Primary hypothesis: The investigators hypothesize that long term (\>2 years) NTZ therapy will slow the rate of whole brain atrophy in patients with Multiple Sclerosis (MS) (as measured by percent change in brain volume), reaching a whole brain atrophy rate similar to that of non-MS controls (a true "disease activity free" state).
Conditions Studied
Study Locations (1)
Colorado
- University of Colorado Anschutz - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2014-07 |
| Est. Completion | 2019-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02588053
The ClinicalTrials.gov registry entry for NCT02588053 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (85% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT02588053 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT02588053 about?
NCT02588053 is a clinical study titled "Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?". Primary Aims: To determine how effective long term Natalizumab (NTZ) therapy is in slowing the progression of whole brain atrophy. Whole brain atrophy rates will be measured through magnetic resonance imaging (MRI) scans and compared between patients with Multiple Sclerosis (MS) who have been using ...
What is the current status of trial NCT02588053?
This trial is currently completed. The enrollment target is 85 participants. The study started on 2014-07. Estimated completion is 2019-01.
What conditions does trial NCT02588053 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
Who is sponsoring clinical trial NCT02588053?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02588053 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.